



## **Metabolic Cofactor Supplementation Reduces Recovery Time in COVID-19 Patients by Nearly 30%**

*A Phase 2 study published Today in medRxiv finds addition of nutritional protocol to standard of care reduces recovery time to 6.6 days in mild-to-moderate COVID-19 patients*

**STOCKHOLM, October 6, 2020:** ScandiBio Therapeutics, a biotechnology company originating from the Swedish national infrastructure Science for Life Laboratory today announces that patients with mild-to-moderate COVID-19 experienced a 29% reduction in recovery time when receiving a nutritional protocol and standard of care of hydroxychloroquine compared to standard of care plus placebo in a Phase 2 clinical study. The additional nutritional support was designed to promote healthy mitochondrial function and reduced average recovery time to 6.6 days in comparison to average placebo recovery time of 9.3 days. COVID-19 has been associated with metabolic conditions such as hypertension, high blood sugar, obesity, high triglycerides and low HDL cholesterol, putting individuals with these conditions at greater risk for worse outcomes. The patients receiving the nutritional protocol consisting of L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR), and L-carnitine tartrate also experienced a significant improvement in liver function.

Results from the study “Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19” were published today on the preprint publication server [medRxiv.org](https://www.medrxiv.org). The research was conducted in partnership with California-based ChromaDex (NASDAQ:CDXC) that provided one of the four ingredients (nicotinamide riboside or Niagen®) through the ChromaDex External Research Program (CERP). The phase 2 clinical study was led by Dr. Adil Mardinoglu and took place at the Umraniye Teaching and Research Hospital, University of Health Sciences, Istanbul, Turkey.

In the open-label, randomized, placebo-controlled, Phase 2 study, 100 outpatient (ambulatory) patients with mild-to-moderate COVID-19 were randomly assigned on a 3:1 basis to receive hydroxychloroquine, which is the standard of care in Turkey, in combination with either a nutritional protocol (combined metabolic cofactors supplementation) or placebo twice per day beginning approximately 24-48 hours after diagnosis. Patients received the standard of care for five days and either the nutritional protocol or placebo for 14 days, with plasma samples collected on day 0 and day 14 to assess biomarkers. Key findings for the 93 patients completing the study include:

- The combination treatment significantly reduced average recovery time compared with the placebo group (6.6 days vs 9.3 days, respectively, an improvement of just over 29%).
- There was a significant reduction in plasma ALT, AST and LDH levels for the combination treatment on day 14 compared to day 0.
- Adverse events were uncommon, benign, and self-limiting.

“This research builds upon a broader understanding of the importance of mitochondrial health in response to metabolic stress. Given the scientific understanding that people with various metabolic conditions have a greater risk of poor outcomes following a COVID-19 diagnosis, it is important to understand the potential benefit of mitochondrial health in aiding patient recovery,” said principal study



investigator Dr. Mardinoglu. “The insights provided by this data warrant further clinical study of this nutrient protocol in combination with standard of care to reduce recovery time from COVID-19. We look forward to the initiation of a Phase 3 study in the near future.”

For additional information: <https://www.medrxiv.org/content/10.1101/2020.10.02.20202614v1>

Contact:

Dr Marianne Hansson, CEO ScandiBio Therapeutics

phone: +46 70 216 60 28, email: [marianne.hansson@gmail.com](mailto:marianne.hansson@gmail.com)

Prof Mathias Uhlen, Chairman of the Board, ScandiBio Therapeutics

email: [mathias.uhlen@scilifelab.se](mailto:mathias.uhlen@scilifelab.se)

---

## ***About***

### ***ScandiBio Therapeutics, Stockholm, Sweden***

ScandiBio Therapeutics is a biotechnology company founded by researchers from the KTH Royal Institute of Technology, Karolinska Institutet and Sahlgrenska Academy in Sweden. The science originates from research conducted at the Science for Life Laboratory in Stockholm (reference Dr Adil Mardinoglu and professor Mathias Uhlén) together with researchers at the Sahlgrenska Academy in Göteborg (reference Professor Jan Borén). A platform for AI-based modelling of biology and medicine has been developed to allow potential treatment of diseases with metabolic dysfunction. The company has developed a combined metabolic cofactor supplementation (CMCS) now in clinical trials aimed to improve for patients with various diseases of metabolic origin.

For more information, see: [www.scandibio.com](http://www.scandibio.com)